Clinical Trials
6 trialsNCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT02970162 2018-12-24
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01377922 2018-01-04
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT01511978 2017-07-11
DAPPER
Jacobus Pharmaceutical
Phase 2 Completed